-
Mashup Score: 3ASH 2024: Changing the Treatment Landscape in Lymphoma - 18 day(s) ago
Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction. Presented at #ASH24 by @timfenske from @MedicalCollege. #lymsm https://t.co/3LOBwc5LP0 https://t.co/O5yn1rF7g6
-
-
Mashup Score: 79Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial - 22 day(s) ago
Loncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet-
Impressive results for CD19 directed ADC loncastuximab tesirine in follicular lymphoma - why was it not developed in FL sooner?! Now published in @TheLancetHaem https://t.co/dx1rFSxG1M (almost all patients CAR T naive) #ASH24 #lymsm https://t.co/wusKCNukF7
-
-
Mashup Score: 0
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma. Presented at #ASH24 by @SehnLaurie from @BCCancer and @UBC. #lymsm https://t.co/MYOofBEYHm https://t.co/QQDEyeou0J
-
-
Mashup Score: 1Lenalidomide Improves Upon Durvalumab in CTCL - 26 day(s) ago
Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial. Presented at #ASH24 by Dr Christiane Querfeld from @cityofhope. #lymsm https://t.co/ZYYnZpelGD https://t.co/y6OYFq23zi
-
-
Mashup Score: 0Paper: A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab - 27 day(s) ago
Program: Oral and Poster Abstracts Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II Hematology Disease Topics & Pathways: Research, Lymphomas, Non-Hodgkin lymphoma, Bispecific Antibody Therapy, Clinical Research, Health outcomes research, Diseases, Indolent lymphoma, Real-world evidence, Treatment Considerations, Biological therapies, Lymphoid Malignancies Pallawi Torka, MD 1, Anthony Masaquel 2 *, Lourenia Cassoli 2 *, David Fox 2 *, Arliene Ravelo 2 * and Ajay
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Many thanks to Dr. @PallawiTorkaMD for your collaboration and to Dr. @guptaarjun90 for pioneering time toxicity as a patient-centered outcome! #ASH24 #lymsm Abstract link: https://t.co/4QLhfdOEev https://t.co/ScpdoKnggJ
-
-
Mashup Score: 0Firi-Cel Produces Durable Remissions After CD19 CAR-T Failure - 28 day(s) ago
Firi-cel can be effective in LBCL patients who had disease progression after a prior CAR T-cell therapy, updated data suggest.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Firi-cel can be effective in LBCL patients who had disease progression after a prior CAR T-cell therapy, updated data suggest. Presented at #ASH24 by @marijnkramer from @StanfordCancer. #lymsm https://t.co/hPuEFaPkyK https://t.co/3C3mT7uA1n
-
-
Mashup Score: 74Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial - 29 day(s) ago
Loncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet-
Impressive results for CD19 directed ADC loncastuximab tesirine in follicular lymphoma - why was it not developed in FL sooner?! Now published in @TheLancetHaem https://t.co/dx1rFSxG1M (almost all patients CAR T naive) #ASH24 #lymsm https://t.co/wusKCNukF7
-
-
Mashup Score: 18In pursuit of a functional cure for follicular lymphoma - 29 day(s) ago
Abstract. We are now a quarter of a century after the transformative impact of rituximab in improving overall survival for patients with follicular lymphom
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
That feeling when your PRO study gets cited in an @ASH_hematology Education Program article!🤩 Thank you to @JudithTrotman1 for highlighting our work as part of a larger research program to utilize PROs in iNHL management & decision-making. #ASH24 #lymsm https://t.co/3mtF8cGG1W https://t.co/hoVZwuCNvE
-
-
Mashup Score: 13Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas - 2 month(s) ago
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Parsaclisib (PI3Ki)+chemo 1L LBCL @YucaiWangMD #ASH24: - 50 pts (7 pola-R-CHP) - RCHOP: ORR 98%, CR 91%, 2-yr PFS 85%, OS 95% - Pola: ORR 100%, CR 100%, 1 relapse, all alive Plans for RCT? Love to see PI3K/Akt/mTOR back in action (see our trial): https://t.co/4f8xc6ygYa #lymsm https://t.co/u4Jj3Arv3P
-
Advances in MCL and FL from #ASH24. With @SehnLaurie of @BCCancer, @timfenske of @MedicalCollege, @poh_christina of @fredhutch & @UW, Dr Sunita Nasta of @PennCancer, @LymphClinician of @cityofhope, @DrMatasar of @RutgersCancer, and more. #lymsm https://t.co/SrtEqdxDTQ